Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: A multicenter, double-blind, double-dummy, randomized, controlled, phase III, non-inferiority trial

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2265-2275

  Rhee, Chin Kook ^a   Chang, Jung Hyun ^b   Choi, Eu Gene ^c   Kim, Hyun Kuk ^d   Kwon, Yong Soo ^e   Kyung, Sun Young ^f   Lee, Ji Hyun ^g   Park, Myung Jae ^h   Yoo, Kwang Ha ⁱ   Oh, Yeon Mok ^j  

^a The Catholic University of Korea   (South Korea)

^b Ewha Womans University   (South Korea)

^c DaeJeon HanKook Hospital   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Chonnam National University Medical School   (South Korea)

^f Gachon University   (South Korea)

^g CHA University   (South Korea)

^h Kyung Hee University College of Medicine   (South Korea)

ⁱ Konkuk University School of Medicine   (South Korea)

^j University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

CAT; Chronic obstructive pulmonary disease; Exacerbation; EXACT PRO; Quinolone; Zabofloxacin

Indexed keywords

MOXIFLOXACIN; ZABOFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; ADVERSE DRUG REACTION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BLURRED VISION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPEPSIA; EPIGASTRIC DISCOMFORT; ERYTHEMA; FACE EDEMA; FATIGUE; FEMALE; FLANK PAIN; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART PALPITATION; HEMATURIA; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; PARESTHESIA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THORAX PAIN; TREATMENT RESPONSE; TREMOR; URETHRA STENOSIS; VARIANT ANGINA PECTORIS; VOMITING; XEROSTOMIA; CLINICAL TRIAL; DRUG MONITORING; LUNG FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 84945551240     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S90948     Document Type: Article

References (19)

1. Pela R, Marchesani F, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis. 1998; 53(3):262–267.
2. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22): 2355–2365.
3. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014;35(1):157–163.
4. Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother. 2006;50(6):2261–2264.
5. Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother. 2006;58(3):684–688.
6. Kosowska-Shick K, Credito K, Pankuch GA, et al. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob Agents Chemother. 2006;50(6):2064–2071.
7. Petitpretz P, Chone C, Tremolieres F. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents. 2007;30(1):52–59.
8. Urueta-Robledo J, Ariza H, Jardim JR, et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir Med. 2006;100(9):1504–1511.
9. Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med. 2000;94(1):18–27.
10. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44(4):501–513.
11. DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin vs azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med. 2000;94(11):1029–1037.
12. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents. 2007;29(1):56–61.
13. Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother. 2002;14(6):597–608.
14. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2004; 23(2):129–137.
15. Liu KX, Xu B, Wang J, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis. 2014;6(3):221–229.
16. Kim HJ, Seol MJ, Park HS, et al. Antimicrobial activity of DW-224a, a new fluoroquinolone, against Streptococcus pneumoniae. J Antimicrob Chemother. 2006;57(6):1256–1258.
17. Park HS, Jung SJ, Kwak JH, Choi DR, Choi EC. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. Int J Antimicrob Agents. 2010;36(1):97–98.
18. Williams L, Shackcloth J, Jung YH, Morrissey I. Activity of DW-224a and comparators against atypical bacterial respiratory pathogens. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30; 2004; Washington, DC.
19. Kim YS, Kim MJ, Back KR, et al. A phase 2, multi-dose, double-blind, randomized, multicenter, safety and efficacy study of zabofloxacin vs moxifloxacin in the treatment of mild to moderate community-acquired pneumonia. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9; 2012; San Francisco, CA.